Spero Therapeutics Announces Innovent License for SP001 and $105M Royalty Financing

What Happened

• Spero Therapeutics (SPRO) announced on July 8, 2026 that it entered into a license agreement with Innovent Biologics granting Spero exclusive global rights (outside Innovent’s China/HK/Taiwan/Macau territory) to develop, manufacture and commercialize Innovent’s anti‑CD40L monoclonal antibody program (SP001/IBI355) and backups. Spero agreed to a $35.0 million upfront payment and up to ~$1.05 billion in development, regulatory and commercial milestone payments, plus tiered royalties (high single‑digit to mid‑teens percent) on net sales. The parties also agreed to certain territory carve‑outs, a five‑year mutual restriction on developing competing anti‑CD40L antibodies in the licensed territory, and other customary terms. Press releases were issued July 14, 2026.
• On July 8, 2026 Spero completed a royalty financing transaction structured through special‑purpose subsidiaries: Issuer sold $105.0 million of senior secured notes (issued net of a $3.15M original issue discount) and sold 65% of certain future GSK milestone/royalty proceeds (after repayment of the Notes) for $1.575 million. The Notes carry 10% annual interest (capitalized if unpaid), mature in nine years, and are secured primarily by the SPV equity and rights to certain GSK proceeds. Spero provided a limited guaranty and will service the transactions. Spero says net proceeds plus existing cash should fund operations into the second half of 2029.

Key Details

• Innovent Agreement date: July 8, 2026; upfront $35.0M; up to ~$1.05B in milestones; tiered royalties (high single‑digit to mid‑teens %). Company to file a U.S. IND within 12 months (subject to allowable delays).
• SP001 (IBI355): third‑generation, Fc‑silent anti‑CD40L IgG1; evaluated in Phase 1 SAD/MAD and a Phase 1b study in Sjögren’s disease; Spero expects to start a Phase 2 trial in IgG4‑related disease in Q2 2027.
• Royalty financing: $105M senior secured Notes issued to NPA purchasers (net of $3.15M OID); 10% interest, 9‑year maturity; collateral includes SPV equity and rights to GSK tebipenem HBr milestone/royalty payments (the “GSK Proceeds”); RPA purchasers bought 65% of purchased GSK Proceeds post‑note for $1.575M, Spero retains 35%.
• Cash runway: Company estimates proceeds plus existing cash will fund operations into the second half of 2029, but says assumptions may prove incorrect.

Why It Matters

• Licensing SP001 adds a clinical‑stage asset (anti‑CD40L) to Spero’s pipeline with upside if clinical development succeeds, but the deal also creates substantial future payment obligations (upfront, milestones, royalties) that would reduce net commercial economics.
• The royalty financing provides immediate non‑dilutive cash tied to future GSK tebipenem HBr payments, extending Spero’s runway into 2029. However, repayment is structured primarily against those GSK proceeds (secured to the SPVs), and Spero’s guarantee is limited—investors should note the financing’s payment source and potential foreclosure triggers on default.
• Near‑term operational milestones to watch: IND filing timing (within ~12 months of July 8, 2026), initiation of the SP001 Phase 2 in IgG4‑RD (targeted Q2 2027), and any recognition of milestone/royalty obligations that would affect future cash flow and margins.